Marc Ansari1, Yves Théoret, Mohamed Aziz Rezgui, Christina Peters, Samira Mezziani, Catherine Desjean, Marie-France Vachon, Martin A Champagne, Michel Duval, Maja Krajinovic, Henrique Bittencourt. 1. *Charles-Bruneau Cancer Center, CHU Sainte-Justine Research Center, Montreal, Canada; †Department of Pediatrics, Onco-Hematology Division, CHU Sainte-Justine, Montreal, Canada; ‡CANSEARCH Research Center, Faculty of Medicine, Geneva University, Geneva, Switzerland; §Clinical Pharmacology Unit, CHU Sainte-Justine Research Center, Montreal, Canada; ¶Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, Canada; ‖Department of Pediatrics, Stem Cell Transplantation Unit, St Anna Children's Hospital, Vienna, Austria; **Department of Pediatrics Onco-Hematology Division, CHU Sainte-Justine Research Center, Montreal, Canada.
Abstract
BACKGROUND AND OBJECTIVE: Intravenous (IV) busulfan (Bu) combined with therapeutic drug monitoring-guided dosing is associated with better event-free survival (EFS), lower transplant-related mortality. But optimal target steady-state concentration (Css) of Bu in children undergoing hematopoietic stem cell transplantation (HSCT) remains unclear. This study aimed to evaluate the relation between Css of Bu and clinical outcomes in children receiving Bu before HSCT. METHODS: This study includes 75 children receiving IV Bu in 16 doses, with first dose assigned based on age. Bu first-dose pharmacokinetic parameters were estimated from Bu plasma concentrations measured at 6 time points by high-performance liquid chromatography. Doses were adjusted at the fifth dose to a target Css of 600-900 ng/mL. Cumulative incidence of overall survival (OS), EFS, transplant-related mortality, acute graft-versus host disease (aGVHD), and other toxicities in relation to Css of Bu were analyzed using Kaplan-Meier curves in univariate and Cox's proportional hazards model in multivariate analysis. RESULTS: After the first dose, median Css was 578 (325-1227) ng/mL. Forty-one patients had Bu IV dose increased by > 10%. Neutrophil and platelet recoveries, grade 2-4 aGVHD, and nonrelapse mortality (NRM) incidences were 90%, 91%, 12%, and 13%, respectively. Relapse incidence was 33%. Incidence of veno-occlusive disease, hemorrhagic cystitis, and lung toxicities were 13%, 24%, and 7%, respectively. OS and EFS were 70% and 58%. First-dose Bu Css >600 ng/mL was associated with a higher NRM (P < 0.001) and grade 2-4 aGVHD (P = 0.04), a lower EFS (P < 0.001), and OS (P = 0.001). CONCLUSIONS: This study demonstrated a significant association between the first-dose pharmacokinetics of Bu and NRM, OS, and EFS. Bu therapeutic drug monitoring provides information that potentially influences outcomes of HSCT in pediatric patients.
BACKGROUND AND OBJECTIVE: Intravenous (IV) busulfan (Bu) combined with therapeutic drug monitoring-guided dosing is associated with better event-free survival (EFS), lower transplant-related mortality. But optimal target steady-state concentration (Css) of Bu in children undergoing hematopoietic stem cell transplantation (HSCT) remains unclear. This study aimed to evaluate the relation between Css of Bu and clinical outcomes in children receiving Bu before HSCT. METHODS: This study includes 75 children receiving IV Bu in 16 doses, with first dose assigned based on age. Bu first-dose pharmacokinetic parameters were estimated from Bu plasma concentrations measured at 6 time points by high-performance liquid chromatography. Doses were adjusted at the fifth dose to a target Css of 600-900 ng/mL. Cumulative incidence of overall survival (OS), EFS, transplant-related mortality, acute graft-versus host disease (aGVHD), and other toxicities in relation to Css of Bu were analyzed using Kaplan-Meier curves in univariate and Cox's proportional hazards model in multivariate analysis. RESULTS: After the first dose, median Css was 578 (325-1227) ng/mL. Forty-one patients had Bu IV dose increased by > 10%. Neutrophil and platelet recoveries, grade 2-4 aGVHD, and nonrelapse mortality (NRM) incidences were 90%, 91%, 12%, and 13%, respectively. Relapse incidence was 33%. Incidence of veno-occlusive disease, hemorrhagic cystitis, and lung toxicities were 13%, 24%, and 7%, respectively. OS and EFS were 70% and 58%. First-dose Bu Css >600 ng/mL was associated with a higher NRM (P < 0.001) and grade 2-4 aGVHD (P = 0.04), a lower EFS (P < 0.001), and OS (P = 0.001). CONCLUSIONS: This study demonstrated a significant association between the first-dose pharmacokinetics of Bu and NRM, OS, and EFS. Bu therapeutic drug monitoring provides information that potentially influences outcomes of HSCT in pediatric patients.
Authors: Imke H Bartelink; Arief Lalmohamed; Elisabeth M L van Reij; Christopher C Dvorak; Rada M Savic; Juliette Zwaveling; Robbert G M Bredius; Antoine C G Egberts; Marc Bierings; Morris Kletzel; Peter J Shaw; Christa E Nath; George Hempel; Marc Ansari; Maja Krajinovic; Yves Théorêt; Michel Duval; Ron J Keizer; Henrique Bittencourt; Moustapha Hassan; Tayfun Güngör; Robert F Wynn; Paul Veys; Geoff D E Cuvelier; Sarah Marktel; Robert Chiesa; Morton J Cowan; Mary A Slatter; Melisa K Stricherz; Cathryn Jennissen; Janel R Long-Boyle; Jaap Jan Boelens Journal: Lancet Haematol Date: 2016-10-13 Impact factor: 18.959
Authors: Nathan J Rodgers; Alexander M Kaizer; Weston P Miller; Kyle D Rudser; Paul J Orchard; Elizabeth A Braunlin Journal: J Inherit Metab Dis Date: 2017-01-04 Impact factor: 4.982
Authors: M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac Journal: Bone Marrow Transplant Date: 2015-09-21 Impact factor: 5.483
Authors: Partow Kebriaei; Claudio Anasetti; Mei-Jie Zhang; Hai-Lin Wang; Ibrahim Aldoss; Marcos de Lima; H Jean Khoury; Brenda M Sandmaier; Mary M Horowitz; Andrew Artz; Nelli Bejanyan; Stefan Ciurea; Hillard M Lazarus; Robert Peter Gale; Mark Litzow; Christopher Bredeson; Matthew D Seftel; Michael A Pulsipher; Jaap-Jan Boelens; Joseph Alvarnas; Richard Champlin; Stephen Forman; Vinod Pullarkat; Daniel Weisdorf; David I Marks Journal: Biol Blood Marrow Transplant Date: 2017-12-25 Impact factor: 5.742